Thr275

Site Information
YSSSGsQtPESENSR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 50702219
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 ) , non-small cell large cell lung carcinoma ( 2 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , HCC78 (pulmonary) ( 2 ) , lung ( 2 ) , NCI-H1781 (pulmonary) ( 2 ) , NCI-H2228 (pulmonary) ( 2 ) , NCI-H3122 (pulmonary) ( 2 ) , NCI-H661 (pulmonary) ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info